Embecta

Embecta Receivables

The Accounts Receivable of Embecta (EMBC) as of Oct 22, 2026 is 145.60 M USD. In the previous year, Accounts Receivable was 194.20 M USD — a change of -25.03% (lower).

Receivables

145.60 MUSD

YoY

-25.03%

Last updated:

Accounts Receivable of Embecta is 2025 145.60 M USD. Accounts Receivable of Embecta was 2024 194.20 M USD. It decreases by -25.03% lower compared to the previous year.

The Embecta Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2019
118.00 M USD
Jan 1, 2020
120.00 M USD
Jan 1, 2021
151.00 M USD
Jan 1, 2022
23.40 M USD
Jan 1, 2023
17.90 M USD
Jan 1, 2024
194.20 M USD
Jan 1, 2025
145.60 M USD
The Embecta Receivables history
YEARReceivablesYoY
145.60 MUSD-25.03%
194.20 MUSD+984.92%
17.90 MUSD-23.50%
23.40 MUSD-84.50%
151.00 MUSD+25.83%
120.00 MUSD+1.69%
118.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Accounts Receivable of Embecta is 145.60 M USD in 2025.

Accounts Receivable of Embecta changed from 194.20 M USD to 145.60 M USD, representing a -25.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Embecta since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Embecta

All Key Metrics — Embecta